Abstract To evaluate gemcitabine efficacy in advanced pancreatic cancer patients after the FOLFIRINOX regimen. Patients with locally-advanced or metastatic pancreatic adenocarcinoma from French and Canadian centers, who were treated with… Click to show full abstract
Abstract To evaluate gemcitabine efficacy in advanced pancreatic cancer patients after the FOLFIRINOX regimen. Patients with locally-advanced or metastatic pancreatic adenocarcinoma from French and Canadian centers, who were treated with the first-line FOLFIRINOX regimen (FFX L1), followed by gemcitabine monotherapy as a second-line treatment (GEM L2), were retrospectively evaluated. Statistical analyses were performed on the demographic, toxicity, and response rate data. Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan–Meier method. Seventy-two patients were reviewed (median age of 63.5 years [range, 32–75 years], men [62%], predominantly pancreatic head tumor location [51%] and metastatic disease [64%] at the time of diagnosis). The objective response rate to GEM-L2 treatment was 8/72 (11%), and 32 patients (44%) experienced a clinical benefit from gemcitabine. Four patients had a partial response to GEM-L2, although they previously showed a progressive response following FFX-L1 treatment. The median OS for the entire cohort was 13.6 months (95% confidence interval [CI]: 2.0–35). The median PFS of the GEM-L2 group was 2.5 months (95% CI: 0.2–10.8) with no statistical differences between patients with controlled or progressive disease on FFX-L1 therapy. Gemcitabine as a second-line treatment for advanced pancreatic adenocarcinoma after FOLFIRINOX failure showed clinical benefits in some patients.
               
Click one of the above tabs to view related content.